131 related articles for article (PubMed ID: 26490305)
1. Association between GWAS-Derived rs966423 Genetic Variant and Overall Mortality in Patients with Differentiated Thyroid Cancer.
Świerniak M; Wójcicka A; Czetwertyńska M; Długosińska J; Stachlewska E; Gierlikowski W; Kot A; Górnicka B; Koperski Ł; Bogdańska M; Wiechno W; Jażdżewski K
Clin Cancer Res; 2016 Mar; 22(5):1111-9. PubMed ID: 26490305
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of GWAS variants associated with differentiated thyroid cancer.
Jendrzejewski JP; Sworczak K; Comiskey DF; de la Chapelle A
Endokrynol Pol; 2019; 70(5):423-429. PubMed ID: 31681970
[TBL] [Abstract][Full Text] [Related]
3. Papillary Thyroid Carcinoma: Association Between Germline DNA Variant Markers and Clinical Parameters.
Jendrzejewski J; Liyanarachchi S; Nagy R; Senter L; Wakely PE; Thomas A; Nabhan F; He H; Li W; Sworczak K; Ringel MD; Kirschner LS; de la Chapelle A
Thyroid; 2016 Sep; 26(9):1276-84. PubMed ID: 27342578
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of papillary thyroid cancer risk loci identified by genome-wide association studies.
Wei WJ; Lu ZW; Wang Y; Zhu YX; Wang YL; Ji QH
Cancer Genet; 2015 Mar; 208(3):68-75. PubMed ID: 25746573
[TBL] [Abstract][Full Text] [Related]
5. Confirmation of papillary thyroid cancer susceptibility loci identified by genome-wide association studies of chromosomes 14q13, 9q22, 2q35 and 8p12 in a Chinese population.
Wang YL; Feng SH; Guo SC; Wei WJ; Li DS; Wang Y; Wang X; Wang ZY; Ma YY; Jin L; Ji QH; Wang JC
J Med Genet; 2013 Oct; 50(10):689-95. PubMed ID: 23847140
[TBL] [Abstract][Full Text] [Related]
6. Risk genetic polymorphism and haplotype associated with papillary thyroid cancer and their relation to associated diseases in Slovak population.
Duffek M; Skerenova M; Halasova E; Sarlinova M; Dzian A; Repiska V; Dobrovodsky A; Mistuna D; Bernadic M; Matakova T
Bratisl Lek Listy; 2022; 123(7):475-48. PubMed ID: 35907052
[TBL] [Abstract][Full Text] [Related]
7. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
[TBL] [Abstract][Full Text] [Related]
8. Fine-mapping of two differentiated thyroid carcinoma susceptibility loci at 9q22.33 and 14q13.3 detects novel candidate functional SNPs in Europeans from metropolitan France and Melanesians from New Caledonia.
Tcheandjieu C; Lesueur F; Sanchez M; Baron-Dubourdieu D; Guizard AV; Mulot C; Laurent-Puig P; Schvartz C; Truong T; Guenel P
Int J Cancer; 2016 Aug; 139(3):617-27. PubMed ID: 26991144
[TBL] [Abstract][Full Text] [Related]
9. Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma.
Liyanarachchi S; Wojcicka A; Li W; Czetwertynska M; Stachlewska E; Nagy R; Hoag K; Wen B; Ploski R; Ringel MD; Kozłowicz-Gudzinska I; Gierlikowski W; Jazdzewski K; He H; de la Chapelle A
Thyroid; 2013 Dec; 23(12):1532-40. PubMed ID: 23659773
[TBL] [Abstract][Full Text] [Related]
10. Significant SNPs have limited prediction ability for thyroid cancer.
Guo S; Wang YL; Li Y; Jin L; Xiong M; Ji QH; Wang J
Cancer Med; 2014 Jun; 3(3):731-5. PubMed ID: 24591304
[TBL] [Abstract][Full Text] [Related]
11. Does the TT Variant of the rs966423 Polymorphism in
Hińcza K; Kowalik A; Pałyga I; Walczyk A; Gąsior-Perczak D; Mikina E; Trybek T; Szymonek M; Gadawska-Juszczyk K; Zajkowska K; Suligowska A; Kuchareczko A; Krawczyk K; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32059462
[TBL] [Abstract][Full Text] [Related]
12. The role of CCNH Val270Ala (rs2230641) and other nucleotide excision repair polymorphisms in individual susceptibility to well-differentiated thyroid cancer.
Santos LS; Gomes BC; Gouveia R; Silva SN; Azevedo AP; Camacho V; Manita I; Gil OM; Ferreira TC; Limbert E; Rueff J; Gaspar JF
Oncol Rep; 2013 Nov; 30(5):2458-66. PubMed ID: 23982724
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center.
Lim JY; Hong SW; Lee YS; Kim BW; Park CS; Chang HS; Cho JY
Thyroid; 2013 Nov; 23(11):1423-30. PubMed ID: 23496275
[TBL] [Abstract][Full Text] [Related]
14. Clinical features of Hispanic thyroid cancer cases and the role of known genetic variants on disease risk.
Estrada-Florez AP; Bohórquez ME; Sahasrabudhe R; Prieto R; Lott P; Duque CS; Donado J; Mateus G; Bolaños F; Vélez A; Echeverry M; Carvajal-Carmona LG
Medicine (Baltimore); 2016 Aug; 95(32):e4148. PubMed ID: 27512836
[TBL] [Abstract][Full Text] [Related]
15. The common genetic variant rs944289 on chromosome 14q13.3 associates with risk of both malignant and benign thyroid tumors in the Japanese population.
Rogounovitch TI; Bychkov A; Takahashi M; Mitsutake N; Nakashima M; Nikitski AV; Hayashi T; Hirokawa M; Ishigaki K; Shigematsu K; Bogdanova T; Matsuse M; Nishihara E; Minami S; Yamanouchi K; Ito M; Kawaguchi T; Kondo H; Takamura N; Ito Y; Miyauchi A; Matsuda F; Yamashita S; Saenko VA
Thyroid; 2015 Mar; 25(3):333-40. PubMed ID: 25562676
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
Xing M; Westra WH; Tufano RP; Cohen Y; Rosenbaum E; Rhoden KJ; Carson KA; Vasko V; Larin A; Tallini G; Tolaney S; Holt EH; Hui P; Umbricht CB; Basaria S; Ewertz M; Tufaro AP; Califano JA; Ringel MD; Zeiger MA; Sidransky D; Ladenson PW
J Clin Endocrinol Metab; 2005 Dec; 90(12):6373-9. PubMed ID: 16174717
[TBL] [Abstract][Full Text] [Related]
17. Investigation of VEGF and IL-8 Gene Polymorphisms in Patients with Differentiated Thyroid Cancer.
Kilic I; Guldiken S; Sipahi T; Palabiyik O; Akker M; Celik O; Soysal-Atile N; Tuncbilek N; Guven HM; Gundogdu AS; Sut N
Clin Lab; 2016 Dec; 62(12):2319-2325. PubMed ID: 28164553
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide copy number analysis in a family with p.G533C RET mutation and medullary thyroid carcinoma identified regions potentially associated with a higher predisposition to lymph node metastasis.
Araujo AN; Moraes L; França MI; Hakonarson H; Li J; Pellegrino R; Maciel RM; Cerutti JM
J Clin Endocrinol Metab; 2014 Jun; 99(6):E1104-12. PubMed ID: 24601688
[TBL] [Abstract][Full Text] [Related]
19. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
20. Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis.
Bernstein J; Virk RK; Hui P; Prasad A; Westra WH; Tallini G; Adeniran AJ; Udelsman R; Sasaki CT; Roman SA; Sosa JA; Prasad ML
Thyroid; 2013 Dec; 23(12):1525-31. PubMed ID: 23682579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
